188 citations
,
October 2014 in “Thyroid” This study found that dabrafenib was well tolerated and led to durable responses in patients with BRAF-mutant differentiated thyroid carcinoma, with a median progression-free survival of 11.3 months.
31 citations
,
March 2014 in “Journal of the European Academy of Dermatology and Venereology” In this study, multiple cutaneous adverse effects were observed in patients with metastatic malignant melanoma receiving BRAF inhibitors, but most were well managed with appropriate treatment.
11 citations
,
June 2023 in “Journal of Cellular Biochemistry” This study suggests that BRAF inhibitors, particularly Encorafenib and Dabrafenib, may have potential applications in wound healing by targeting specific proteins involved in the healing process in murine models.
6 citations
,
April 2013 in “Current Dermatology Reports” This review discusses the cutaneous side effects associated with vemurafenib and ipilimumab in metastatic melanoma treatment and emphasizes the importance of dermatologists in managing these skin eruptions; it reports no new clinical results.
3 citations
,
June 2021 in “PLOS ONE” This study found that topical application of the BRAF inhibitor vemurafenib improved wound healing and promoted hair follicle regeneration in a diabetic murine model.